Cargando…
High expression of interleukin-enhancer binding factor 3 predicts poor prognosis in patients with lung adenocarcinoma
Interleukin-enhancer binding factor 3 (ILF3) is a double-stranded RNA-binding protein that has been reported to contribute to the occurrence and progression of various malignant tumors. The aim of the present study was to evaluate the prognostic value of ILF3 and to apply this knowledge to avoid exc...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
D.A. Spandidos
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7039148/ https://www.ncbi.nlm.nih.gov/pubmed/32194712 http://dx.doi.org/10.3892/ol.2020.11330 |
_version_ | 1783500769210662912 |
---|---|
author | Xu, Zhangyan Huang, Hua Li, Xing Ji, Cheng Liu, Yifei Liu, Xiaojuan Zhu, Jun Wang, Zhendong Zhang, Haijian Shi, Jiahai |
author_facet | Xu, Zhangyan Huang, Hua Li, Xing Ji, Cheng Liu, Yifei Liu, Xiaojuan Zhu, Jun Wang, Zhendong Zhang, Haijian Shi, Jiahai |
author_sort | Xu, Zhangyan |
collection | PubMed |
description | Interleukin-enhancer binding factor 3 (ILF3) is a double-stranded RNA-binding protein that has been reported to contribute to the occurrence and progression of various malignant tumors. The aim of the present study was to evaluate the prognostic value of ILF3 and to apply this knowledge to avoid excessive medical treatment in patients with lung adenocarcinoma (LUAD). ILF3 expression in a discovery set consisting of tumor and peri-tumor tissue microarrays was analyzed using immunohistochemical methods. The mRNA level of ILF3 was subsequently analyzed in a validation set downloaded from The Cancer Genome Atlas. The Kaplan-Meier method, univariate and multivariate Cox analyses, decision curve analysis and nomogram models were used to evaluate the prognostic value of ILF3. ILF3 expression was upregulated in tumor tissues compared with peri-tumor tissues and was negatively associated with the overall survival time of patients with LUAD in the discovery and validation sets. Moreover, ILF3 expression was used for risk stratification in patients with tumor-node-metastasis stages II–IV and poor-to-moderate tumor differentiation. ILF3 expression was identified as an independent predictor of adverse prognosis for patients with LUAD in the discovery and validation sets. Finally, nomogram models for the 3- and 5 year survival time of patients with LUAD revealed that ILF3 expression may be used to improve the predictive accuracy of the prognosis and to avoid excessive medical treatment for certain patients with the disease. Overall, the data obtained in the current study revealed that high ILF3 expression was associated with poor prognosis, and demonstrated that ILF3, as a potential independent risk factor, may improve the hierarchical postoperative management of patients with LUAD. |
format | Online Article Text |
id | pubmed-7039148 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | D.A. Spandidos |
record_format | MEDLINE/PubMed |
spelling | pubmed-70391482020-03-19 High expression of interleukin-enhancer binding factor 3 predicts poor prognosis in patients with lung adenocarcinoma Xu, Zhangyan Huang, Hua Li, Xing Ji, Cheng Liu, Yifei Liu, Xiaojuan Zhu, Jun Wang, Zhendong Zhang, Haijian Shi, Jiahai Oncol Lett Articles Interleukin-enhancer binding factor 3 (ILF3) is a double-stranded RNA-binding protein that has been reported to contribute to the occurrence and progression of various malignant tumors. The aim of the present study was to evaluate the prognostic value of ILF3 and to apply this knowledge to avoid excessive medical treatment in patients with lung adenocarcinoma (LUAD). ILF3 expression in a discovery set consisting of tumor and peri-tumor tissue microarrays was analyzed using immunohistochemical methods. The mRNA level of ILF3 was subsequently analyzed in a validation set downloaded from The Cancer Genome Atlas. The Kaplan-Meier method, univariate and multivariate Cox analyses, decision curve analysis and nomogram models were used to evaluate the prognostic value of ILF3. ILF3 expression was upregulated in tumor tissues compared with peri-tumor tissues and was negatively associated with the overall survival time of patients with LUAD in the discovery and validation sets. Moreover, ILF3 expression was used for risk stratification in patients with tumor-node-metastasis stages II–IV and poor-to-moderate tumor differentiation. ILF3 expression was identified as an independent predictor of adverse prognosis for patients with LUAD in the discovery and validation sets. Finally, nomogram models for the 3- and 5 year survival time of patients with LUAD revealed that ILF3 expression may be used to improve the predictive accuracy of the prognosis and to avoid excessive medical treatment for certain patients with the disease. Overall, the data obtained in the current study revealed that high ILF3 expression was associated with poor prognosis, and demonstrated that ILF3, as a potential independent risk factor, may improve the hierarchical postoperative management of patients with LUAD. D.A. Spandidos 2020-03 2020-01-22 /pmc/articles/PMC7039148/ /pubmed/32194712 http://dx.doi.org/10.3892/ol.2020.11330 Text en Copyright: © Xu et al. This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License (https://creativecommons.org/licenses/by-nc-nd/4.0/) , which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made. |
spellingShingle | Articles Xu, Zhangyan Huang, Hua Li, Xing Ji, Cheng Liu, Yifei Liu, Xiaojuan Zhu, Jun Wang, Zhendong Zhang, Haijian Shi, Jiahai High expression of interleukin-enhancer binding factor 3 predicts poor prognosis in patients with lung adenocarcinoma |
title | High expression of interleukin-enhancer binding factor 3 predicts poor prognosis in patients with lung adenocarcinoma |
title_full | High expression of interleukin-enhancer binding factor 3 predicts poor prognosis in patients with lung adenocarcinoma |
title_fullStr | High expression of interleukin-enhancer binding factor 3 predicts poor prognosis in patients with lung adenocarcinoma |
title_full_unstemmed | High expression of interleukin-enhancer binding factor 3 predicts poor prognosis in patients with lung adenocarcinoma |
title_short | High expression of interleukin-enhancer binding factor 3 predicts poor prognosis in patients with lung adenocarcinoma |
title_sort | high expression of interleukin-enhancer binding factor 3 predicts poor prognosis in patients with lung adenocarcinoma |
topic | Articles |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7039148/ https://www.ncbi.nlm.nih.gov/pubmed/32194712 http://dx.doi.org/10.3892/ol.2020.11330 |
work_keys_str_mv | AT xuzhangyan highexpressionofinterleukinenhancerbindingfactor3predictspoorprognosisinpatientswithlungadenocarcinoma AT huanghua highexpressionofinterleukinenhancerbindingfactor3predictspoorprognosisinpatientswithlungadenocarcinoma AT lixing highexpressionofinterleukinenhancerbindingfactor3predictspoorprognosisinpatientswithlungadenocarcinoma AT jicheng highexpressionofinterleukinenhancerbindingfactor3predictspoorprognosisinpatientswithlungadenocarcinoma AT liuyifei highexpressionofinterleukinenhancerbindingfactor3predictspoorprognosisinpatientswithlungadenocarcinoma AT liuxiaojuan highexpressionofinterleukinenhancerbindingfactor3predictspoorprognosisinpatientswithlungadenocarcinoma AT zhujun highexpressionofinterleukinenhancerbindingfactor3predictspoorprognosisinpatientswithlungadenocarcinoma AT wangzhendong highexpressionofinterleukinenhancerbindingfactor3predictspoorprognosisinpatientswithlungadenocarcinoma AT zhanghaijian highexpressionofinterleukinenhancerbindingfactor3predictspoorprognosisinpatientswithlungadenocarcinoma AT shijiahai highexpressionofinterleukinenhancerbindingfactor3predictspoorprognosisinpatientswithlungadenocarcinoma |